Oelschlager Kristen M 4

What Happened

• Kristen M. Oelschlager, Chief Operating Officer of Castle Biosciences (CSTL), sold a total of 8,586 shares in open-market transactions on July 1, 2026. The sales consisted of 8,186 shares at a weighted-average price of $24.40 (proceeds $199,738) and 400 shares at a weighted-average price of $24.78 (proceeds $9,912), for combined proceeds of approximately $209,650. These were sales (not purchases), and thus are generally considered routine disposition rather than a buy signal.

Key Details

• Transaction date: 2026-07-01; Form 4 filed: 2026-07-06 (no late filing flag noted in the provided data).
• Reported prices/amounts: 8,186 shares @ $24.40 ($199,738); 400 shares @ $24.78 ($9,912); total ~8,586 shares / $209,650.
• Price details: One sale executed across multiple trades at prices ranging $23.73–$24.72 (weighted avg reported); the other executed across multiple trades at $24.77–$24.79 (weighted avg reported). The filer offers to provide full trade-level details on request (see footnotes).
• Plan/holding notes: Transactions were made under a Rule 10b5-1 trading plan adopted by Ms. Oelschlager on March 17, 2026. Some shares are held by the Fritz Shorter Trust (the reporting person and spouse are trustees/beneficiaries).
• Shares owned after the transaction: Not specified in the excerpt provided.

Context

• The sales were executed under a pre-established 10b5-1 plan, which means the trades were scheduled in advance and are commonly used to avoid trading on nonpublic information; this is important context for interpreting insider sales. Sales do not necessarily indicate negative views about the company — they can be for diversification, tax, or liquidity reasons.